دورية أكاديمية
أعرض في EDS

Ferroptosis Modulation: Potential Therapeutic Target for Glioblastoma Treatment.

التفاصيل البيبلوغرافية
العنوان: Ferroptosis Modulation: Potential Therapeutic Target for Glioblastoma Treatment.
المؤلفون: de Souza I; Department of Clinical and Experimental Oncology, Federal University of Sao Paulo (UNIFESP), Sao Paulo 04037-003, Brazil., Ramalho MCC; Laboratory of Cell Cycle, Center of Toxins, Immune Response and Cell Signaling (CeTICS), Butantan Institute, Sao Paulo 05503-001, Brazil., Guedes CB; Department of Clinical and Experimental Oncology, Federal University of Sao Paulo (UNIFESP), Sao Paulo 04037-003, Brazil., Osawa IYA; Laboratory of Cell Cycle, Center of Toxins, Immune Response and Cell Signaling (CeTICS), Butantan Institute, Sao Paulo 05503-001, Brazil., Monteiro LKS; Department of Clinical and Experimental Oncology, Federal University of Sao Paulo (UNIFESP), Sao Paulo 04037-003, Brazil., Gomes LR; Laboratory of Cell Cycle, Center of Toxins, Immune Response and Cell Signaling (CeTICS), Butantan Institute, Sao Paulo 05503-001, Brazil., Rocha CRR; Department of Clinical and Experimental Oncology, Federal University of Sao Paulo (UNIFESP), Sao Paulo 04037-003, Brazil.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2022 Jun 21; Vol. 23 (13). Date of Electronic Publication: 2022 Jun 21.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Ferroptosis* , Glioblastoma*/drug therapy , Glioblastoma*/pathology , Glioma*, Humans ; Iron/metabolism ; Neoplasm Recurrence, Local
مستخلص: Glioblastoma multiforme is a lethal disease and represents the most common and severe type of glioma. Drug resistance and the evasion of cell death are the main characteristics of its malignancy, leading to a high percentage of disease recurrence and the patients' low survival rate. Exploiting the modulation of cell death mechanisms could be an important strategy to prevent tumor development and reverse the high mortality and morbidity rates in glioblastoma patients. Ferroptosis is a recently described type of cell death, which is characterized by iron accumulation, high levels of polyunsaturated fatty acid (PUFA)-containing phospholipids, and deficiency in lipid peroxidation repair. Several studies have demonstrated that ferroptosis has a potential role in cancer treatment and could be a promising approach for glioblastoma patients. Thus, here, we present an overview of the mechanisms of the iron-dependent cell death and summarize the current findings of ferroptosis modulation on glioblastoma including its non-canonical pathway. Moreover, we focused on new ferroptosis-inducing compounds for glioma treatment, and we highlight the key ferroptosis-related genes to glioma prognosis, which could be further explored. Thereby, understanding how to trigger ferroptosis in glioblastoma may provide promising pharmacological targets and indicate new therapeutic approaches to increase the survival of glioblastoma patients.
References: Front Oncol. 2020 Jun 23;10:897. (PMID: 32656078)
Nat Cell Biol. 2014 Dec;16(12):1180-91. (PMID: 25402683)
Int J Mol Sci. 2021 Apr 27;22(9):. (PMID: 33925597)
Cell. 2012 May 25;149(5):1060-72. (PMID: 22632970)
Front Genet. 2021 Nov 08;12:753680. (PMID: 34819946)
Free Radic Biol Med. 2019 Mar;133:221-233. (PMID: 30266679)
Adv Mater. 2019 Dec;31(51):e1904197. (PMID: 31595562)
Transl Cancer Res. 2022 Apr;11(4):603-614. (PMID: 35571655)
Commun Biol. 2020 Aug 17;3(1):450. (PMID: 32807853)
Redox Biol. 2020 Feb;30:101413. (PMID: 31896509)
Biosci Rep. 2021 Dec 22;41(12):. (PMID: 34726238)
Eur J Pharmacol. 2021 Apr 5;896:173898. (PMID: 33508284)
Cancers (Basel). 2021 Dec 07;13(24):. (PMID: 34944790)
Cell Chem Biol. 2022 May 19;29(5):799-810.e4. (PMID: 34520742)
Mol Med Rep. 2021 Oct;24(4):. (PMID: 34396451)
Blood. 2006 Aug 15;108(4):1388-94. (PMID: 16609065)
Front Aging Neurosci. 2020 Mar 02;12:47. (PMID: 32210783)
Int J Gen Med. 2022 Jan 06;15:253-270. (PMID: 35023963)
Front Neurosci. 2018 Jul 10;12:466. (PMID: 30042655)
Oxid Med Cell Longev. 2022 May 11;2022:9925919. (PMID: 35602105)
Front Cell Dev Biol. 2022 Jan 31;9:812422. (PMID: 35174170)
Biochemistry. 2020 Feb 11;59(5):637-638. (PMID: 32003211)
Nat Nanotechnol. 2016 Nov;11(11):977-985. (PMID: 27668796)
Front Cell Dev Biol. 2021 Dec 07;9:788451. (PMID: 34950662)
Biosci Rep. 2020 Jun 26;40(6):. (PMID: 32452511)
Nat Chem Biol. 2017 Jan;13(1):91-98. (PMID: 27842070)
Nature. 2019 Nov;575(7784):693-698. (PMID: 31634899)
Cancer Drug Resist. 2021;4:17-43. (PMID: 34337348)
Front Cell Dev Biol. 2020 Jul 09;8:538. (PMID: 32733879)
Cell Res. 2016 Sep;26(9):1021-32. (PMID: 27514700)
J Nucl Med. 2021 Jul 1;62(7):949-955. (PMID: 33246980)
Front Cell Dev Biol. 2021 May 19;9:675555. (PMID: 34095147)
Annu Rev Nutr. 2018 Aug 21;38:97-125. (PMID: 30130469)
J Cell Physiol. 2021 Apr;236(4):2988-3000. (PMID: 32964440)
Front Pharmacol. 2020 Apr 03;11:377. (PMID: 32308621)
Front Cell Dev Biol. 2022 Jan 31;10:817643. (PMID: 35174152)
J Neurochem. 2006 Jan;96(2):561-72. (PMID: 16336627)
Oncol Rep. 2020 Jan;43(1):147-158. (PMID: 31789401)
Nature. 2014 May 1;509(7498):105-9. (PMID: 24695223)
Crit Rev Oncol Hematol. 2020 Nov;155:103095. (PMID: 32927333)
Exp Mol Med. 2020 Feb;52(2):192-203. (PMID: 32060354)
Biochem Biophys Res Commun. 2019 Oct 20;518(3):590-597. (PMID: 31445705)
PLoS Biol. 2018 May 24;16(5):e2006203. (PMID: 29795546)
Biochem Biophys Res Commun. 2021 Feb 5;539:56-63. (PMID: 33421769)
Biomaterials. 2021 Nov;278:121163. (PMID: 34601197)
Cells. 2020 Dec 01;9(12):. (PMID: 33271924)
Nat Med. 2017 Jan;23(1):120-127. (PMID: 27869804)
Front Physiol. 2019 Feb 26;10:139. (PMID: 30863316)
J Cell Mol Med. 2022 Jan;26(2):449-461. (PMID: 34894053)
Redox Biol. 2017 Aug;12:8-17. (PMID: 28212525)
J Biol Chem. 1999 Apr 23;274(17):11455-8. (PMID: 10206947)
Cancer Lett. 2018 Aug 1;428:21-33. (PMID: 29702192)
Oncogene. 2008 Mar 6;27(11):1618-28. (PMID: 17828297)
Biol Pharm Bull. 2020;43(3):480-487. (PMID: 32115506)
Onco Targets Ther. 2020 Oct 20;13:10631-10640. (PMID: 33116640)
Cell. 2014 Jan 16;156(1-2):317-331. (PMID: 24439385)
Cell Rep. 2019 Feb 5;26(6):1544-1556.e8. (PMID: 30726737)
Proteomics. 2019 Sep;19(18):e1800311. (PMID: 30888116)
Anticancer Drugs. 2020 Jan;31(1):27-34. (PMID: 31490283)
Eur J Pharmacol. 2022 Apr 15;921:174860. (PMID: 35278406)
Chem Rev. 2011 Oct 12;111(10):5944-72. (PMID: 21861450)
Nat Chem Biol. 2020 Dec;16(12):1351-1360. (PMID: 32778843)
Biochim Biophys Acta Gen Subj. 2017 Aug;1861(8):1893-1900. (PMID: 28552631)
ACS Chem Biol. 2015 Jul 17;10(7):1604-9. (PMID: 25965523)
J Pharmacol Sci. 2022 Mar;148(3):300-306. (PMID: 35177209)
Front Pharmacol. 2022 Apr 28;13:898679. (PMID: 35571123)
Hum Cell. 2022 Jan;35(1):238-249. (PMID: 34791597)
Eur Rev Med Pharmacol Sci. 2020 Mar;24(5):2585-2600. (PMID: 32196629)
Oxid Med Cell Longev. 2021 Dec 26;2021:2915019. (PMID: 34987700)
Oncogenesis. 2017 Aug 14;6(8):e371. (PMID: 28805788)
J Exp Clin Cancer Res. 2019 Sep 13;38(1):402. (PMID: 31519193)
Cell Mol Life Sci. 2016 Jun;73(11-12):2405-10. (PMID: 27048813)
Front Cell Dev Biol. 2021 Jun 14;9:660005. (PMID: 34277607)
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):E4966-75. (PMID: 27506793)
ChemMedChem. 2018 Jan 22;13(2):164-177. (PMID: 29235250)
Biochem Biophys Res Commun. 2017 Jan 15;482(3):419-425. (PMID: 28212725)
Oncol Lett. 2020 Oct;20(4):122. (PMID: 32863935)
Oncotarget. 2016 Jul 26;7(30):48081-48092. (PMID: 27344172)
Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Oct;3(10):836-843. (PMID: 29941380)
Cell Death Dis. 2018 Jul 9;9(7):753. (PMID: 29988039)
Medicina (Kaunas). 2022 Feb 20;58(2):. (PMID: 35208642)
Cell Death Dis. 2018 Aug 6;9(8):841. (PMID: 30082680)
Front Oncol. 2020 Nov 20;10:590861. (PMID: 33330074)
Yonsei Med J. 2021 Sep;62(9):843-849. (PMID: 34427071)
Elife. 2014 May 20;3:e02523. (PMID: 24844246)
Med Sci Monit. 2020 Jun 02;26:e921947. (PMID: 32484805)
J Biol Chem. 1984 Aug 10;259(15):9345-7. (PMID: 6146611)
Cell. 2017 Oct 5;171(2):273-285. (PMID: 28985560)
Life Sci. 2020 Apr 15;247:117425. (PMID: 32057904)
Cancer Med. 2021 Nov;10(22):8100-8113. (PMID: 34612013)
Genes Dis. 2016 May 11;3(3):198-210. (PMID: 30258889)
J Immunother Cancer. 2020 Nov;8(2):. (PMID: 33188036)
Nat Chem Biol. 2017 Jan;13(1):81-90. (PMID: 27842066)
Cancer Cell. 2019 Jun 10;35(6):830-849. (PMID: 31105042)
Nature. 2017 Jul 27;547(7664):453-457. (PMID: 28678785)
Cell Death Discov. 2021 Oct 23;7(1):311. (PMID: 34689169)
J Cell Mol Med. 2021 Mar;25(6):3080-3090. (PMID: 33594759)
Oncol Rep. 2015 Mar;33(3):1465-74. (PMID: 25585997)
Metab Brain Dis. 2022 Apr 19;:. (PMID: 35438378)
Biochem J. 2012 Mar 15;442(3):453-64. (PMID: 22364280)
Acta Pharmacol Sin. 2021 Oct;42(10):1690-1702. (PMID: 34112960)
Nature. 2019 Nov;575(7784):688-692. (PMID: 31634900)
J Clin Neurosci. 2016 Dec;34:1-5. (PMID: 27578526)
Cancer Discov. 2019 Sep;9(9):1161-1163. (PMID: 31481405)
Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S2-8. (PMID: 27668386)
PLoS One. 2016 Oct 6;11(10):e0164285. (PMID: 27711253)
Ann Transl Med. 2020 Feb;8(4):124. (PMID: 32175417)
Int J Biol Sci. 2022 Jan 1;18(2):841-857. (PMID: 35002529)
Protein Cell. 2021 Aug;12(8):599-620. (PMID: 33000412)
Oncotarget. 2017 May 9;8(31):51164-51176. (PMID: 28881638)
Genes Dev. 2020 Apr 1;34(7-8):526-543. (PMID: 32079652)
Oncogene. 2021 Feb;40(8):1425-1439. (PMID: 33420375)
Oncol Lett. 2020 Sep;20(3):2689-2700. (PMID: 32782585)
Front Cell Dev Biol. 2021 Nov 15;9:739097. (PMID: 34869322)
Free Radic Res. 2021 Jul;55(7):853-864. (PMID: 34323631)
Biochem Soc Trans. 2020 Oct 30;48(5):2253-2259. (PMID: 33125483)
Nature. 2021 May;593(7860):586-590. (PMID: 33981038)
Front Neurol. 2022 Mar 10;13:829926. (PMID: 35359663)
ACS Cent Sci. 2020 Jan 22;6(1):41-53. (PMID: 31989025)
Cell. 2017 Oct 19;171(3):628-641.e26. (PMID: 29053969)
Cell Death Differ. 2018 Mar;25(3):486-541. (PMID: 29362479)
J Clin Invest. 2018 Aug 1;128(8):3341-3355. (PMID: 29939160)
Cancer Treat Res. 2015;163:103-15. (PMID: 25468228)
Mol Brain. 2022 Apr 28;15(1):36. (PMID: 35484595)
Oncogenesis. 2021 Feb 12;10(2):15. (PMID: 33579899)
Mol Cancer. 2022 Feb 12;21(1):47. (PMID: 35151318)
Redox Biol. 2019 May;23:101107. (PMID: 30692038)
Front Oncol. 2022 Apr 21;12:841418. (PMID: 35530303)
ACS Chem Biol. 2022 Feb 18;17(2):483-491. (PMID: 35128925)
Oncogene. 2017 Oct 5;36(40):5593-5608. (PMID: 28553953)
معلومات مُعتمدة: #2019/26268-6, #2019/21745-0, #2019/27080-0, #2013/07467-1, #2019/15320-7, #2019/19435-3 Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
فهرسة مساهمة: Keywords: cell death; ferroptosis; glioma treatment
المشرفين على المادة: E1UOL152H7 (Iron)
تواريخ الأحداث: Date Created: 20220709 Date Completed: 20220712 Latest Revision: 20220716
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9266903
DOI: 10.3390/ijms23136879
PMID: 35805884
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms23136879